Advances in immunotherapy for neuroendocrine neoplasms / 中华胃肠外科杂志
Chinese Journal of Gastrointestinal Surgery
;
(12): 861-866, 2021.
Article
in Chinese
| WPRIM
| ID: wpr-942983
ABSTRACT
Neuroendocrine neoplasms (NEN) is a rare and heterogeneous tumor. Different pathologic morphology, differentiation, grade and clinical stages of the tumors had various treatment and prognosis. Patients with recurrent or metastatic NEN have limited treatment options and poor prognosis. In recent years, PD-1 pathway blockade has become integral components of disease management for many cancers. Immunotherapy is being explored in NEN. Studies have shown that the efficacy of immune monotherapy in NEN is limited, and it can be considered for selected patients. Biomarkers for predicting efficacy of immunotherapy include PD-L1 expression, TMB-H, MSI-H/dMMR, etc. Combined regimens of anti-CTLA-4 and anti-PD-1/PD-L1 inhibitors, and immune checkpoint inhibitor combined with anti-angiogenic drugs or chemotherapy are promising in patients with NEN, and it is worthwhile to further explore of the responding populations.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Biomarkers, Tumor
/
Neuroendocrine Tumors
/
Microsatellite Instability
/
B7-H1 Antigen
/
Immunotherapy
/
Neoplasms
Limits:
Humans
Language:
Chinese
Journal:
Chinese Journal of Gastrointestinal Surgery
Year:
2021
Type:
Article
Similar
MEDLINE
...
LILACS
LIS